TGTX — TG Therapeutics Share News
0.000.00%
Last trade - 00:00- $8.57bn
- $8.77bn
- $616.29m
Brief: Tg Therapeutics Reports Second Quarter 2026 Financial Results And Raises Briumvi® Revenue Guidance
TG Therapeutics Q2 product revenue rises 70% on BRIUMVI sales
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Toll Brothers, TG Therapeutics, CECO Environmental
TG Therapeutics rises as early-stage data shows benefit in rare muscle weakness disease
TG Therapeutics rises on data for subcutaneous multiple sclerosis drug
U.S. STOCKS ON THE MOVE-Ollie's Bargain Outlet Holdings, Steel Dynamics
TG Therapeutics rises on positive early data for subcutaneous multiple sclerosis drug
Brief: TG Therapeutics Announces Publication Of Post-HOC Data From The Phase 3 Ultimate I & Ii Trials In Treatment Naive Patients With Relapsing Forms Of MS Published In Frontiers In Immunology
Brief: TG Therapeutics Says Phase 3 Enhance Trial Met Its Primary Endpoint
TG Therapeutics Q1 revenue rises, lifts 2026 outlook
Brief: TG Therapeutics Secures An Additional $500 Million In Non-Dilutive Capital From Blue Owl And Expands Share Repurchase Program To $300 Million
TG Therapeutics Q4 revenue rises on BRIUMVI sales, but profit dips
U.S. STOCKS ON THE MOVE-SpyGlass, Agomab, Piper Sandler, Molina
U.S. STOCKS ON THE MOVE-Microchip, Under Armour, Avery Dennison
U.S. STOCKS ON THE MOVE-Biogen, Bloom Energy, Ubiquiti
TG Therapeutics rises on new data for autoimmune therapy
U.S. STOCKS ON THE MOVE-Cognizant, Adient, Cintas